NANJING, China, Nov. 1,
2013 /PRNewswire/ -- Simcere Pharmaceutical Group
(NYSE: SCR), a leading pharmaceutical company specializing in the
development, manufacturing, and marketing of branded generic and
proprietary pharmaceuticals in China, today announced that it will report its
unaudited financial results for the third quarter ended
September 30, 2013 on Thursday, November 14, 2013, before the market
opens in the United States.
Simcere's management will host an earnings conference call on the
same day at 8 a.m. ET (Thursday, November 14, at 9 p.m. Beijing /
Hong Kong time).
To access the conference call, please dial:
|
International
toll:
|
+65.6723.9381
|
|
United States
toll-free:
|
+1.866.519.4004
|
|
United States
toll:
|
+1.845.675.0437
|
|
China Domestic
toll:
|
800.819.0121
|
|
China Domestic mobile
toll:
|
400.620.8038
|
|
Hong Kong
toll:
|
+852.2475.0994
|
Please ask to be connected to Q3 2013 Simcere Pharmaceutical
Group Earnings Conference Call and provide the following passcode:
94745140
Simcere will also broadcast a live audio webcast of the
conference call. The broadcast will be available by visiting the
"Investor Relations" section of the company's web site at
www.simcere.com.
Following the earnings conference call, an archive of the
call will be available by dialing:
|
United States
toll-free:
|
+1.855.452.5696
|
|
United States
toll:
|
+1.646.254.3697
|
The passcode for replay participants is 94745140. The
telephone replay also will be archived on the "Investor Relations"
section of the company's website for seven days following the
earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading
pharmaceutical company specializing in the development,
manufacturing, and marketing of branded and proprietary
pharmaceuticals in China. Simcere
concentrates its research and development efforts on the treatment
of diseases with high incidence and/or mortality rates and for
which there is a clear demand for more effective pharmacotherapy
such as cancer, strokes, cardiovascular disease, infectious
diseases and pain. For more information about Simcere
Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts:
Email: ir@simcere.com
|
In
Nanjing:
|
In the United
States:
|
|
Vivien
Liang
|
Cindy
Zheng
|
|
Simcere
Pharmaceutical Group
|
Brunswick
Group
|
|
Tel:
86-25-8556-6666*8857
|
Tel:
1-212-333-3810
|
|
|
|
In
Beijing:
|
|
|
Yue Yu
|
|
|
Brunswick
Group
|
|
|
Tel:
86-10-5960-8600
|
|
SOURCE Simcere Pharmaceutical Group
